10-KPeriod: FY2025

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2025

Filed February 11, 2026For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) has filed its 2025 10-K, reporting on a year characterized by strategic advancements in its product pipeline and ongoing operational management. The company's performance is underpinned by its diverse portfolio, with a strong emphasis on research and development to fuel future growth and maintain a competitive edge in the biopharmaceutical market. Investors will want to note the company's ongoing efforts in acquisitions, divestitures, and licensing, which are crucial for portfolio optimization and addressing patent expirations. Key areas of focus for the investor include the company's robust pipeline, intellectual property protection, and market access strategies. Management's Discussion and Analysis (MD&A) section will provide critical insights into the financial condition, results of operations, and risk factors, offering a comprehensive view of the company's financial health and future outlook. Understanding the competitive landscape, pricing pressures, and regulatory environment is also paramount for assessing BMY's long-term prospects and resilience.

Financial Highlights

56 data points
Beta

Revenue

$48.19B

71.1% Gross Margin

Net Income

$7.05B

14.6% Net Margin

EPS (Diluted)

$3.46

Total Assets

$90.04B

Cash & Equivalents

$10.21B

Free Cash Flow

$12.85B

Financial Statements
Beta
Revenue$48.19B
Cost of Revenue$13.94B
Gross Profit$34.26B
R&D Expenses$9.95B
SG&A Expenses$7.27B
Operating Expenses$38.87B
Net Income$7.05B
EPS (Basic)$3.47
EPS (Diluted)$3.46
Shares Outstanding (Basic)2.03B
Shares Outstanding (Diluted)2.04B

Key Highlights

  • 1BMY's 2025 10-K details its strategic initiatives including acquisitions, divestitures, and licensing, crucial for pipeline expansion and portfolio management.
  • 2The report emphasizes the company's commitment to Research and Development (R&D) as a primary driver of innovation and future revenue streams.
  • 3Intellectual Property (IP) and Product Exclusivity are highlighted as critical assets, with strategies in place to protect these valuable components.
  • 4The company outlines its Marketing, Distribution, and Customer engagement strategies, essential for successful product launches and market penetration.
  • 5Risk Factors section addresses potential challenges including competition, pricing constraints, and regulatory hurdles that could impact financial performance.
  • 6Financial statements provide a detailed look at the company's earnings, balance sheet, and cash flow for the fiscal year ending December 30, 2025.

Frequently Asked Questions

Based on the 2025 10-K, BMY's strategic priorities appear to center on leveraging its R&D pipeline for innovation, managing its product portfolio through strategic acquisitions, divestitures, and licensing, and navigating the competitive and regulatory landscape to ensure market access and growth.

The company emphasizes the importance of its intellectual property and product exclusivity. Strategies likely include robust R&D to develop new blockbuster drugs, pursuing strategic partnerships and licensing agreements, and potentially exploring M&A to fill any portfolio gaps created by patent expirations.

The filing indicates key risks include intense competition within the biopharmaceutical sector, pricing pressures from payers and governments, stringent government regulation of drug development and marketing, and potential challenges in R&D success and manufacturing quality assurance.

Detailed financial information is available in Item 8 of the 10-K filing, which includes the Consolidated Statements of Earnings and Comprehensive Income/(Loss), Consolidated Balance Sheets, and Consolidated Statements of Cash Flows, along with accompanying notes to the financial statements.